Reuters - A possible risk of sudden cardiac death is a concern with AstraZeneca Plc’s (AZN.L) Seroquel XR as the company seeks wider approval for the blockbuster schizophrenia drug, U.S. reviewers said in documents released on Friday.
Reuters - A possible risk of sudden cardiac death is a concern with AstraZeneca Plc’s (AZN.L) Seroquel XR as the company seeks wider approval for the blockbuster schizophrenia drug, U.S. reviewers said in documents released on Friday.
